Septerna (NASDAQ:SEPN) Stock Rating Lowered by Wall Street Zen

Key Points

• Septerna has been downgraded from a "hold" to a "sell" rating by Wall Street Zen, indicating a negative outlook for the company's stock.
• Despite the downgrade, consensus ratings from other analysts show that Septerna still holds a "Moderate Buy" with an average target price of $26.75.
• In its most recent quarterly earnings report, Septerna reported a loss of $(0.56) EPS, significantly missing estimates, with a net margin of -12,053.03%.

Septerna (NASDAQ:SEPN - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday.

Several other research firms also recently issued reports on SEPN. HC Wainwright reiterated a "buy" rating and set a $26.00 price target on shares of Septerna in a research note on Thursday, August 21st. Wells Fargo & Company upped their price target on Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a research note on Friday, May 16th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price target on shares of Septerna in a research note on Friday, September 5th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, Septerna presently has a consensus rating of "Moderate Buy" and an average price target of $26.75.

Septerna Trading Down 0.2%

SEPN stock traded down $0.03 during mid-day trading on Friday, hitting $14.44. The stock had a trading volume of 118,702 shares, compared to its average volume of 635,511. Septerna has a 1-year low of $4.17 and a 1-year high of $28.99. The company has a fifty day moving average of $12.54 and a 200 day moving average of $9.51. The stock has a market capitalization of $643.81 million and a price-to-earnings ratio of -1.43.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.51). Septerna had a negative return on equity of 31.52% and a negative net margin of 12,053.03%.The firm had revenue of $0.12 million during the quarter, compared to analyst estimates of $22.50 million. As a group, sell-side analysts expect that Septerna will post -7.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Septerna

Several large investors have recently added to or reduced their stakes in SEPN. BVF Inc. IL raised its holdings in Septerna by 79.3% in the 1st quarter. BVF Inc. IL now owns 4,396,124 shares of the company's stock valued at $25,454,000 after acquiring an additional 1,944,100 shares in the last quarter. TRV GP VI LLC raised its holdings in shares of Septerna by 33.6% in the 1st quarter. TRV GP VI LLC now owns 4,211,659 shares of the company's stock worth $24,386,000 after buying an additional 1,059,203 shares in the last quarter. Checkpoint Capital L.P. acquired a new position in shares of Septerna in the 1st quarter worth approximately $4,776,000. ADAR1 Capital Management LLC acquired a new position in shares of Septerna in the 1st quarter worth approximately $4,174,000. Finally, Soleus Capital Management L.P. acquired a new position in shares of Septerna in the 4th quarter worth approximately $15,467,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.